Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BIPHETAMINE 20 vs BIPHETAMINE 12.5
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.
Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.
Narcolepsy,Attention Deficit Hyperactivity Disorder (ADHD) (FDA-approved for these indications as a schedule II controlled substance)
Attention Deficit Hyperactivity Disorder (ADHD),Narcolepsy
10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.
12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.
0.5–1.5 hours for the immediate-release component; terminal elimination half-life of the total amphetamine salts is approximately 10–13 hours in adults
9-14 hours in children and adolescents; clinical effects typically last 4-6 hours due to distribution and tolerance. Terminal half-life may be longer in adults with higher body fat (up to 20 hours).
Metabolized primarily by the liver via CYP2D6 and to a lesser extent by CYP3A4. Major metabolic pathways include hydroxylation, deamination, and oxidation to benzoic acid derivatives. Excretion is primarily renal.
Hepatic metabolism via CYP2D6 and other pathways; primarily deamination and oxidation.
Renal (90% as unchanged drug and metabolites, with approximately 30% unchanged); fecal (10%)
Renal: 70-80% as unchanged drug and metabolites (primarily deaminated metabolites); fecaroute is negligible. Urinary p H-dependent: acidification increases renal clearance, alkalinization decreases it.
16–20% (primarily to albumin)
20-40%, primarily to albumin and alpha-1 acid glycoprotein.
3–4 L/kg; indicates extensive tissue distribution
3.2-5.6 L/kg, indicating extensive tissue distribution; crosses blood-brain barrier readily.
Oral: 75–100% (first-pass metabolism minimal)
Oral: 75-100% (amphetamines have high and consistent oral bioavailability).
e GFR <30 m L/min: contraindicated; e GFR 30-59 m L/min: use with caution, reduce dose by 50%.
GFR <30 m L/min: avoid use; GFR 30-60 m L/min: reduce dose by 50% and monitor; GFR >60 m L/min: no adjustment.
Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 50%; Child-Pugh class C: use not recommended.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children ≥6 years: initial 5 mg orally once daily; titrate by 5 mg weekly to max 20 mg/day.
6-12 years: 6.25 mg or 12.5 mg once daily in the morning, may increase by 6.25 mg weekly up to 37.5 mg/day; weight-based: 0.3-0.8 mg/kg/day, max 37.5 mg/day.
Initiate at 5 mg orally once daily; increase slowly with monitoring for cardiovascular effects.
Initiate at 6.25 mg once daily in the morning, increase cautiously by 6.25 mg weekly; monitor for cardiovascular and psychiatric effects; maximum daily dose 37.5 mg.
WARNING: ABUSE AND DEPENDENCE. Biphetamine contains amphetamine and dextroamphetamine, which have a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular adverse events.
Biphetamine has a high potential for abuse and dependence. Prolonged use may lead to drug dependence. Misuse may cause sudden death or serious cardiovascular events.
Cardiovascular: risk of sudden death or serious cardiovascular events, especially in patients with pre-existing cardiac abnormalities.,CNS effects: may cause psychotic or manic symptoms, aggression, seizures, and visual disturbances.,Growth suppression: may cause weight loss and growth retardation in children.,Peripheral vasculopathy: including Raynaud's phenomenon.,Serotonin syndrome: when co-administered with serotonergic drugs.,Potential for immediate hypersensitivity reactions.
Risk of serious cardiovascular events including sudden death in patients with pre-existing structural cardiac abnormalities or other serious heart problems,Risk of hypertension and tachycardia,Risk of psychiatric adverse events such as exacerbation of pre-existing psychosis, mania, or aggression,Risk of seizures in patients with a history of seizures,Long-term suppression of growth in children
Hypersensitivity to amphetamine or dextroamphetamine,Concurrent use or within 14 days of MAO inhibitors (hypertensive crisis risk),Glaucoma,Hyperthyroidism,Agitated states,History of drug abuse,Cardiovascular disease (e.g., advanced arteriosclerosis, symptomatic cardiovascular disease, moderate to severe hypertension),Motor tics or Tourette's syndrome (worsening possible)
History of drug abuse,Cardiovascular disease including symptomatic cardiovascular disease, advanced arteriosclerosis, hypertension, hyperthyroidism,Glaucoma,Agitated states,History of seizures or tics,Concomitant use of MAOIs or within 14 days of MAOI use
Avoid foods and beverages high in caffeine or other stimulants (e.g., coffee, tea, cola, chocolate) as they may increase stimulant effects and risk of adverse reactions. Acidic foods (e.g., citrus fruits, juices) and vitamin C can decrease absorption; separate intake by at least 1 hour. Maintain a consistent meal schedule to minimize appetite suppression.
Avoid high-fat meals as they may delay absorption. Limit caffeine intake (coffee, tea, colas) as it may increase stimulant effects and risk of side effects. Acidic foods/juices (e.g., orange juice, grapefruit juice) can decrease absorption; take medication with water. Maintain adequate hydration.
First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth weight, neonatal withdrawal syndrome, and potential for behavioral effects. Avoid use unless benefit outweighs risk.
First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second and third trimesters: Risk of prematurity, low birth weight, and neonatal withdrawal symptoms (e.g., irritability, poor feeding). Amphetamines may cause vasoconstriction leading to placental insufficiency.
Contraindicated in breastfeeding. Amphetamines are excreted in human milk (M/P ratio not established) and may cause infant agitation, poor feeding, and growth suppression. Discontinue drug or nursing.
Biphetamine is excreted into breast milk. M/P ratio is approximately 2.5–7.5. Use is contraindicated during breastfeeding due to potential for adverse effects on infant development (e.g., irritability, poor weight gain).
No established dosage adjustments in pregnancy; use lowest effective dose for shortest duration. Increased clearance during pregnancy may require dose increase, but safety data insufficient. Avoid in pregnancy unless essential.
No established guidelines; avoid use in pregnancy. If unavoidable, use lowest effective dose with careful monitoring. Increased clearance may necessitate higher doses, but risks outweigh benefits.
Monitor for hypertension and tachycardia; avoid use in patients with cardiovascular disease, hyperthyroidism, or glaucoma. Use with caution in patients with a history of substance abuse. May exacerbate tics and Tourette syndrome. Do not administer late in the day due to insomnia risk. Discontinue if seizures occur.
Biphetamine 12.5 is a mixed amphetamine salt product (D-amphetamine and L-amphetamine). Monitor for cardiovascular events, especially in patients with pre-existing conditions. Avoid use within 14 days of MAOIs. Use with caution in patients with hypertension, hyperthyroidism, glaucoma, or history of drug abuse. Assess for tics or Tourette's syndrome. Monitor growth in pediatric patients. May cause withdrawal symptoms upon abrupt discontinuation.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Take the first dose upon awakening; avoid taking late in the day to prevent sleep problems.,Do not chew or crush tablets; swallow whole with water.,Avoid alcohol and caffeine while taking this medication.,Report any chest pain, palpitations, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how it affects you.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not increase dose or frequency without consulting your doctor.,Avoid taking late in the day to prevent insomnia.,Report any chest pain, shortness of breath, or fainting immediately.,May cause dizziness or blurred vision; avoid driving until you know how the medication affects you.,Do not stop abruptly; your doctor will taper the dose to avoid withdrawal symptoms.,Inform your doctor if you have a history of heart problems, high blood pressure, seizures, or mental health conditions.,Avoid alcohol and other CNS stimulants.,Store at room temperature away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BIPHETAMINE 20 vs BIPHETAMINE 12.5, answered by our medical review team.
BIPHETAMINE 20 is a Central Nervous System Stimulant that works by Biphetamine 20 is a fixed-dose combination of amphetamine and dextroamphetamine, which are non-catecholamine sympathomimetic amines that promote the release of dopamine and norepinephrine from presynaptic neurons, and inhibit their reuptake, thereby increasing synaptic concentrations of these neurotransmitters in the central nervous system.. BIPHETAMINE 12.5 is a Central Nervous System Stimulant that works by Biphetamine 12.5 is a central nervous system stimulant that increases the levels of norepinephrine and dopamine in the synaptic cleft by inhibiting the reuptake of these neurotransmitters and by promoting their release from presynaptic terminals.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BIPHETAMINE 20 and BIPHETAMINE 12.5 depend on the specific clinical indication. These are both Central Nervous System Stimulant agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BIPHETAMINE 20 is: 10-20 mg orally once daily in the morning; may increase to 20 mg twice daily (morning and noon) if needed.. The standard adult dose of BIPHETAMINE 12.5 is: 12.5 mg orally once daily in the morning, may titrate weekly by 12.5 mg to maximum 75 mg/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BIPHETAMINE 20 and BIPHETAMINE 12.5 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BIPHETAMINE 20 is classified as Category C. First trimester: Limited data; possible increased risk of oral clefts and cardiovascular defects based on some studies. Second and third trimesters: Risk of prematurity, low birth . BIPHETAMINE 12.5 is classified as Category C. First trimester: Possible increased risk of congenital malformations (e.g., heart defects, oral clefts) based on limited human data; animal studies show fetal abnormalities. Second. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.